Statins and fibrates for preventing melanoma

Cochrane Database of Systematic Reviews

Volumn 2005, Issue 4, 2005, Pages

  Dellavalle, Robert ^a   Drake, Amanda ^b   Graber, Marla ^b   Pointer, Lauren ^c   Johnson, Kathryn ^b   Mcnealy, Kristie ^b   Schilling, Lisa ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CLOFIBRATE; DEXTROTHYROXINE; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; CLOFIBRIC ACID; HYPOCHOLESTEROLEMIC AGENT;

CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DYSPLASTIC NEVUS; GENDER; HISTOLOGY; HUMAN; INCIDENCE; INTERVENTION STUDY; MELANOMA; MELANOMA SKIN CANCER; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR;

ANTICHOLESTEREMIC AGENTS; CLOFIBRIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MELANOMA; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 33644875727     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003697.pub2     Document Type: Review

References (148)

1. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al.Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1996;156(18):2085-92.
2. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, et al.Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. The American journal of cardiology 2000;86(3):257-62.
3. Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. The American journal of cardiology 1993;71:393-400.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
5. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al.Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364(9436):771-7.
6. Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, et al.Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). The American journal of cardiology 1997;80(3):287-93.
7. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, et al.Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. The American journal of cardiology 2001;87(9):1074-9.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615-22.
9. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al.Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. American journal of hypertension: journal of the American Society of Hypertension 1996;9(4 Pt 1):342-60.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288(23):2998-3007.
11. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al.ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005;293(13):1595-608.
12. Ericsson CG. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. European heart journal 1998;19 Suppl H:37-41.
13. Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B, et al.Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Journal of the American College of Cardiology 1998;32(6):1648-56.
14. de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). European heart journal 1996;17 Suppl F:37-42.
15. de Faire U, Ericsson CG, Hamsten A, Nilsson J. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Drugs under experimental and clinical research 1995;21(3):105-24.
16. Behar S, Graff E, Reicher-Reiss H, Boyko V, Benderly M, Shotan A, et al.Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group. European heart journal 1997;18(1):52-9.
17. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, et al.Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993;71(11):909-15.
18. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 1998;19 Suppl H:H42-7.
19. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102(1):21-7.
20. Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, Hartley LH, et al.Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. The American journal of cardiology 1995;76(9):98C-106C.
21. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al.Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98(9):839-44.
22. Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, et al.Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarcion: the Cholesterol and Recurrent Events Trial (CARE). The American journal of cardiology 1991;68:1436-46.
23. Sacks FM, Pfeffer MA, Moye LA, Rolleau JL, Rutherford JD, Cole TG, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996;335(14):1001-9.
24. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. European journal of clinical pharmacology 1991;40 Suppl 1:S49-51.
25. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al.Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. Journal of the American College of Cardiology 1986;8(6):1245-55.
26. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). The American journal of cardiology 2005;95(2):254-7.
27. Coronary Drug Project Research Group. The Coronary Drug Project: design, methods, and baseline results. Circulation 1973;47(suppl I):1-179.
28. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al.Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39(12):1577-83.
29. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, et al.Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991;14(4):308-17.
30. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al.Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 1987;317(20):1237-45.
31. Heinonen OP, Huttunen JK, Manninen V, Manttari M, Koskinen P, Tenkanen L, et al.The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. Journal of internal medicine 1994;235(1):41-9.
32. Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, Teppo L, et al.The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. Journal of internal medicine 1994;235(1):31-9.
33. Huttunen JK, Manninen V, Manttari M, Koskinen P, Romo M, Tenkanen L, et al.The Helsinki Heart Study: central findings and clinical implications. Annals of medicine 1991;23(2):155-9.
34. Manttari M, Elo O, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al.The Helsinki Heart Study: basic design and randomization procedure. European heart journal 1987;8 Suppl I:1-29.
35. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325(7373):1139.
36. Meade TW. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421]. Current controlled trials in cardiovascular medicine 2001;2(4):195-204.
37. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, et al.Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. Journal of the American College of Cardiology 2001;38(1):56-63.
38. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al.Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105(20):2341-6.
39. [No authors listed]. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. The American journal of cardiology 1995;76(7):474-9.
40. [No authors listed]. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). The American journal of cardiology 1995;76(12):899-905.
41. Dumont JM. Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS). Controlled Clinical Trials 1993;14(3):209-28.
42. Vos J, de Feyter PJ, Kingma JH, Emanuelsson H, Legrand V, Winkelmann B, et al.Evolution of coronary atherosclerosis in patients with mild coronary artery disease studied by serial quantitative coronary angiography at 2 and 4 years follow-up. The Multicenter Anti-Atheroma Study (MAAS) Investigators. European heart journal 1997;18(7):1081-9.
43. Belcaro G, Laurora G, Cesarone MR, De Sanctis MT, Renton S, Veller M, et al.Non-invasive ultrasonic biopsy in the classification of early arterial lesions and in the evaluation of the rate of progression of arteriosclerosis. Panminerva medica 1992;34(3):107-14.
44. Cesarone MR, Laurora G, De Sanctis MT, Pomante P, Belcaro G. Progression of lesions of the arterial wall evaluated by ultrasonic biopsy in asymptomatic subjects and in diabetic and hyperlipidemic patients treated with bezafibrate. A 4-year follow-up. [Italian]. Minerva Cardioangiologica 1992;40(1-2):15-21.
45. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al.Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285(12):1585-91.
46. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. The Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group. New England Journal of Medicine 1999;341(6):410-18.
47. Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, et al.Rationale and design of the department of veterans affairs high-density lipoprotein cholesterol intervention trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. The American journal of cardiology 1993;71:45-52.
48. Heady JA. A cooperative trial on the primary prevention of ischaemic heart disease using clofibrate: design, methods, and progress. Bulletin of the World Health Organization 1973;48:243-56.
49. [No authors listed]. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984;2(8403):600-4.
50. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. The American journal of cardiology 1995;76(9):113C-117C.
51. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. [see comments.]. New England Journal of Medicine 1995;333(20):1301-7.
52. Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al.Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European heart journal 2002;23(3):207-15.
53. The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of scottish men aged 45-64 years: trial design. Journal of clinical epidemiology 1992;45(8):849-60.
54. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286(1):64-70.
55. Arad Y, Newstein D, Roth M, Guerci AD. Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. Controlled Clinical Trials 2001;22(5):553-72.
56. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, et al.Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). American Journal of Cardiology 2000;86(12):1293-8.
57. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al.Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current Medical Research & Opinion 2002;18(4):220-8.
58. Avellone G, Di Garbi V, Cordova R, Panno AV, Raneli G, De Simone R, et al.Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion. Fibrinolysis 1993;7(6):416-21.
59. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C, ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. American Journal of Cardiology 2001;88(3):265-9.
60. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, et al. ADvicor Versus Other Cholesterol-Modulating Agents Trial= Evaluation. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). American Journal of Cardiology 2003;91(6):667-72.
61. Campeau L Knatterud GL, Domanski M, Hunninghake DB, White CW, Geller NL, et al.The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. New England Journal of Medicine 1997;336(3):153-62.
62. Carmena R, Deoya M, Gomezgerique J, Mata P, Serrano S, Franco M, et al.Pravastatin, cholestyramine, and bezafibrate in patients with heterozygous familial hypercholesterolemia: the Spanish multicenter pravastatin study. Cardiovascular Risk Factors 1996;6(1):55-61.
63. Chung N, Cho SY, Choi DH, Zhu JR, Lee K, Lee PY, et al.STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target. Clinical Therapeutics 2001;23(6):858-70.
64. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96.
65. Corominas V, de Oya O, Escobar J, Anguera V, Arino A. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia]. ESTUDIO CLINICO MULTICENTRICO, DOBLE CIEGO Y RANDOMIZADO PARA VALORAR LA EFICACIA Y TOLERANCIA DE BINIFIBRATO VERSUS GEMFIBROZIL EN HIPERLIPIDEMIAS TIPO IIa, IIb Y IV. Anales De Medicina Interna 1993;10(11):537-41.
66. Diabetes Atherosclerosis Intervetion Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.[erratum appears in Lancet 2001 Jun 9;357(9271):1890]. Lancet. 2001;357(9260):905-10.
67. Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, Insull W Jr, et al. Worldwide Expanded Dose Simvastatin Study Group. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutrition Metabolism & Cardiovascular Diseases 2000;10(5):253-62.
68. Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE, Crijns HJ, et al.Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). American Journal of Cardiology 2000;86(6):635-8.
69. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, et al.Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21(4):641-8.
70. The ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003;107(3):422-8.
71. Garcia-Otin AL, Civeira F, Aristegui R, Diaz C, Recalde D, Sol JM, et al. The ATOMIX Study Group. Atorvastatin in Mixed dyslipidemia. Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. European Journal of Clinical Investigation 2002;32(6):421-8.
72. Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, et al.Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes, Obesity & Metabolism 2000;2(6):355-62.
73. GISSI Study Group. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). [see comments.]. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 2000;1(12):810-20.
74. Hagenaars T, Gussenhoven EJ, Poldermans D, van Urk H, van der Lugt A. Rationale and design for the SARIS trial; effect of statin on atherosclerosis and vascular remodeling assessed with intravascular sonography. Effect of Statin on Atherosclerosis and vascular Remodeling assessed with Intravascular Sonography. Cardiovascular Drugs & Therapy 2001;15(4):339-43.
75. Hanefeld M, Deslypere JP, Ose L, Durrington PN, Farnier M, Schmage N. Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study. Journal of International Medical Research 1999;27(3):115-29.
76. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al.Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003;361(9374):2024-31.
77. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
78. Humphries SE, Luong LA, Talmud PJ, Frick MH, Kesaniemi YA, Pasternack A, et al.The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 1998;139(1):49-56.
79. Hunninghake D, Insull W, Knopp R, Davidson M, Lohrbauer L, Jones P, et al.Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. American Journal of Cardiology 2001;88(6):635-9.
80. Illingworth DR, Crouse JR 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, et al. Simvastatin Atorvastatin HDL Study Group. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Current Medical Research & Opinion 2001;17(1):43-50.
81. Ito H, Ouchi Y, Ohashi Y, Saito Y, Ishikawa T, Nakamura H, et al.A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). Journal of Atherosclerosis & Thrombosis 2001;8(2):33-44.
82. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. American Journal of Cardiology 1997;79(9):1248-52.
83. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [erratum appears in American Journal of Cardiology 1998 Jul 1;82(1):128]. American Journal of Cardiology 1998;81(5):582-7.
84. Kawaguchi A, Mitsudo K, Nobuyoshi M, Minamino R, Hayasaki K, Nakashima M, et al. ATHEROMA Study Group. Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline. Journal of Cardiovascular Risk 2002;9(1):7-16.
85. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, et al.Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Investigational New Drugs 2001;19(1):81-3.
86. MacMahon M, Kirkpatrick C, Cummings CE, Clayton A, Robinson PJ, Tomiak RH, et al.A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutrition Metabolism & Cardiovascular Diseases 2000;10(4):195-203.
87. Markwood TT, Kent SM, Coyle LC, Flaherty PJ, O'Malley PG, Taylor AJ. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. American Heart Journal 2001;141(3):342-7.
88. McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. American Journal of Medicine 1998;104(2):137-43.
89. McPherson R, Hanna K, Agro A, Braeken A. Canadian Cerivastatin Study Group. Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness. Clinical Therapeutics 2001;23(9):1492-507.
90. Michels KB, Braunwald E. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. JAMA 2002 Jun 19;287(23):3130-2.
91. The MIRACL Study Group. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. Indian Heart Journal 2001;53(2):237.
92. Muls E, De Backer G, Brohet C, Heller F, LIPI-GOAL investigators. The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial. Acta Cardiologica 2001;56(2):109-14.
93. The Newcastle Clofibrate Study Group. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. British Medical Journal 1971;4(5790):767-75.
94. Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group. Current Medical Research & Opinion 1999;15(3):228-40.
95. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000;150(2):429-36.
96. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. New England Journal of Medicine 2003;336(3):153-62.
97. Santos AF, Keitel E, Bittar AE, Neumann J, Fuchs FD, Goldani JC, et al.Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplantation Proceedings 2001;33(1-2):1194-5.
98. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, et al.Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). Journal of the American College of Cardiology 2002;39(4):610-6.
99. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. [see comments.]. JAMA 2001;285(13):1711-8.
100. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROSPER study group. PROspective Study of Pravastatin in the= Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623-30.
101. Sirtori CR, Bianchi G, Bond MG, D'Alo G, Gallus G, Liberatore S, et al.Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: The CAIUS Study. International Journal of Cardiac Imaging 1995;11 Suppl (2):119-24.
102. Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. British Medical Journal 1971;4(5790):775-84.
103. Stelmach WJ, Rush DR, Brucker PC, Schaefer EJ, Holverson HE, Kane WJ, et al.Diet and exercise and gemfibrozil therapy for the management of dyslipidemia: a CEN study. Clinical Experience Network. Journal of Family Practice 1993;36(4):401-8.
104. Syvanne M, Taskinen MR, Nieminen, Manninen V, Kesaniemi YA, Pasternack A, et al.A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography Trial. Controlled Clinical Trials 1997;18(1):93-119.
105. Teo K, Burton J, Buller C, Plante S, Yokoyama S, Montague T. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotension-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis (SCAT). Canadian Journal of Cardiology 1997;13(6):591-9.
106. The Veterans Adminstration Cooperative Study Group. The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke 1973;4(4):684-93.
107. Vichayanrat A, Study Investigators of DESIRES-Z. Dose-expanded study in the reinforcement of efficacy of simvastatin. Journal of the Medical Association of Thailand 2002;85(4):438-45.
108. Wenke K, Meiser B, Theiry J, Nagel D, von Scheidt, Steinbeck G, et al.Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation 1997;96(5):1398-402.
109. West MS, Herd JA, Ballantyne CM, Pownall HJ, Simpson S, Gould L, et al.The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Controlled Clinical Trials 1996;17(6):550-83.
110. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al.Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. Journal of Hypertension 2001;19(6):1139-47.
111. LDS 2004. Ongoing study unclear.
112. Lauterbach KW, Binnen T, Evers T, Harnischmacher U, Ludwig D, Hanrath P, et al.Primary prevention of stroke: RESPECT. European heart journal 2000;2(Suppl D):D51-3.
113. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 2005;352(14):1425-35.
114. American Cancer Society. Cancer Statistics 2004: A presentation from the American Cancer Society. Available at: http://www.cancer.org/downloads/PRO/Cancer%20Statistics%202004.ppt. Accessed on: April 20, 2005.
115. Albert VA, Koh HK, Geller AC, Miller DR, Prout MN, Lew RA. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. Journal of the American Academy of Dermatology 1990;23:308-10.
116. Armstrong BK, English DR. Cutaneous Malignant Melanoma. In: Schottenfeld D, Fraumeni JF Jr editor(s). Cancer epidemiology and prevention. 2nd Edition. New York: Oxford University Press, 1996:1282-312.
117. Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, et al.Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Journal of Clinical Oncology 2001;19:3635-48.
118. Begg CB. The search for cancer risk factors: when can we stop looking?. American Journal of Public Health 2001;91(3):360-4.
119. Berwick M. Epidemiology: Current Trends, Risk Factors, and Environmental Concerns. In: Balch CM, Houghton AN, Sober AJ, Soong S-J editor(s). Cutaneous melanoma. 3rd Edition. St. Louis, Mo: Quality Medical Pub., 1998:551-71.
120. Buchwald H. Cholesterol inhibition, cancer and chemotherapy. Lancet 1992;339:1154-6.
121. Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, et al.Atorvastatin prevents RhoC isoprenylation, invasion and metastasis in human melanoma cells. Molecular Cancer Therapeutics 2003;2:941-8.
122. Criqui MH. Cholesterol, primary and secondary prevention, and all-cause mortality. Annals of Internal Medicine 1991;115:973-6.
123. Dellavalle RP, Nicholas MK, Schilling LM. Melanoma chemoprevention: a role for statins or fibrates?. American Journal of Therapeutics 2003;10(3):203-10.
124. Feleszko W, Zagozdzon R, Golab J, Jakobisiak M. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. European Journal of Cancer 1998;34:406-11.
125. Feleszko W, Mlynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, et al.Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. International Journal of Cancer 2002;100(1):111-8.
126. Fumagalli R, Grossi E, Paoletti P, Paoletti R. Studies on lipids in brain tumors. Journal of Neurochemistry 1964;11:561-5.
127. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. Journal of Clinical Oncology 2004;22(12):2388-94.
128. Grabacka M, Placha W, Plonka PM, Pajak S, Urbanska K, Laidler P, et al.Inhibition of melanoma metastases by fenofibrate. Archives of Dermatological Research 2004;296(2):54-8.
129. Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Archives of Dermatology 1998;134:103-4.
130. Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V, et al.Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 1995;13:314-24.
131. Lenz M. Cholesterol based antineoplastic strategies. Anticancer research 1997;17(2A):1143-6.
132. Lim HW, Cooper K. The health impact of solar radiation and prevention strategies. Report of the Environment Council, American Academy of Dermatology. Journal of the American Academy of Dermatology 1999;41:81-99.
133. Littman ML, Taguchi T, Mosbach EH. Effect of cholesterol free, fat free diet, and hypocholesterolemic agents on growth of transplantable animal tumors. Cancer Chemotherapy Reports 1966;50:25-45.
134. Muldoon, MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
135. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
136. Nordenberg J, Goldwasser I, Zoref-Shani E, Beery E, Sidi Y. Inhibition of B16 melanoma cell proliferation and alterations in p21 ras expression induced by interceptors of signal transduction pathways. Israeli Journal of Medical Science 1996;32:1153-7.
137. Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. 2nd Edition. Oxford, UK: Oxford University Press, 2000:83.
138. Prassanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and phenylacetate against glioma cells. Journal of Neurochemistry 1996;66:710-6.
139. Rigel DS. Identification of those at highest risk for development of malignant melanoma. Advances in Dermatology 1995;10:151-71.
140. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st Century. CA: a cancer journal for clinicians 2000;50:215-36.
141. Shellman YG, Kelly D, Ribble D, Miller L, Gendall J, VanBuskirk K, et al.Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Research 2005;15:In Press.
142. Sleijfer S, van der Gaast A, Planting AS, Stoter G, Verweij J. The potential of statins as part of anti-cancer treatment. European journal of cancer (Oxford, England: 1990) 2005;41(4):516-22.
143. Swerdlow AJ, English JS, MacKie RM, O'Doherty CJ, Hunter JA, Clark J, et al.Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma. BMJ 1988;297:647-50.
144. Thomas L, Tranchand P, Berard F, Secchi T, Colin C, Moulin G. Semiological value of ABCDE criteria in the diagnosis of cutaneous pigmented tumors. Dermatology 1998;197:11-7.
145. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. Journal of the American Academy of Dermatology 1998;38:681-6.
146. Versluis AJ, van Geel PJ, Oppelaar H, van Berkel TJ, Bijsterbosch MK. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. British Journal of Cancer 1996;74:525-32.
147. Walsh P, Gibbs P, Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. Journal of the American Academy of Dermatology 2000;42:480-9.
148. Weinstock MA. Early detection of melanoma. JAMA 2000;284:886-9.